hydroxyurea has been researched along with Thalassemias in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although, several reports have detailed that hydroxyurea can ameliorate the clinical course of adult and pediatric patients with sickle cell anemia (Hb S or beta(S)), few clinical studies have been carried out in patients with beta(S)/beta-thalassemia." | 9.09 | Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. ( Aquino, A; Maggio, A; Renda, D; Renda, MC; Rigano, P; Rodgers, GP, 2001) |
| "In view of easy affordability, better acceptability, minimal toxicity, the need of infrequent monitoring and its potential effectiveness, low and fixed dose of hydroxyurea is suitable for treatment of patients with HbSβ(+) -thalassemia in resource poor setting." | 7.81 | Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation. ( Das, K; Dehury, S; Kullu, BK; Meher, S; Mohapatra, AK; Patel, DK; Patel, NK; Patel, S; Purohit, P; Sahoo, LK, 2015) |
| "Hydroxyurea (HU) is a well-known chemotherapeutic agent that has been used largely for the treatment of various myeloproliferative conditions over the past 20 years." | 5.33 | Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. ( Darzi, H; Karimi, M; Yavarian, M, 2005) |
| "The authors studied the long-term clinical and hematological response to hydroxyurea (HU) therapy in young patients, with either S/beta-thalassemia (beta(thal)) (8 patients) or SS (6 patients)." | 5.11 | Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea. ( Kanavakis, E; Kattamis, A; Kattamis, C; Ladis, V; Lagona, E; Metaxotou-Mavrommati, A; Orfanou, I; Psichou, F, 2004) |
| "Although, several reports have detailed that hydroxyurea can ameliorate the clinical course of adult and pediatric patients with sickle cell anemia (Hb S or beta(S)), few clinical studies have been carried out in patients with beta(S)/beta-thalassemia." | 5.09 | Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. ( Aquino, A; Maggio, A; Renda, D; Renda, MC; Rigano, P; Rodgers, GP, 2001) |
| "Hydroxyurea (HU) has been widely used in clinical practice to manage patients with non-transfusion dependent thalassemia (NTDT)." | 4.12 | The use of hydroxyurea in the real life of MIOT network: an observational study. ( Allò, M; Filosa, A; Maggio, A; Meloni, A; Messina, G; Pepe, A; Pistoia, L; Quarta, A; Quota, A; Ricchi, P; Rigano, P; Rosso, R; Spasiano, A, 2022) |
| "In view of easy affordability, better acceptability, minimal toxicity, the need of infrequent monitoring and its potential effectiveness, low and fixed dose of hydroxyurea is suitable for treatment of patients with HbSβ(+) -thalassemia in resource poor setting." | 3.81 | Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation. ( Das, K; Dehury, S; Kullu, BK; Meher, S; Mohapatra, AK; Patel, DK; Patel, NK; Patel, S; Purohit, P; Sahoo, LK, 2015) |
| "Hydroxyurea represents a privileged choice of treatment in the severe forms of SCD in children, for homozygous SCD-SS as well as for double heterozygote SCD-S/beta thalassemia." | 3.74 | [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases]. ( Bejaoui, M; Mellouli, F, 2008) |
| "Hydroxyurea, which has shown to induce fetal haemoglobin synthesis in human erythroid cells, is currently recommended for the treatment of sickle cell disease." | 2.94 | Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial. ( Manamperi, A; Mettananda, C; Mettananda, S; Premawardhena, A; Wickramarathne, N; Yasara, N, 2020) |
| "Beta thalassemia major (TM) is the most frequent form of transfusion-dependent inherited anemia in India." | 2.66 | Thalassemia: Common Clinical Queries in Management. ( Bansal, D; Lal, A, 2020) |
| " However, application of these drugs at large is not yet justified because a series of questions concerning their long-term efficacy, the correct dosage and timing, their tolerance and toxicity, and the potential long-term dangers, including mutagenicity are still unresolved." | 2.40 | New therapies for the haemoglobinopathies. ( Loukopoulos, D, 1997) |
| "Sickle beta+thalassemia is considered to be a mild form of sickle cell disease." | 1.72 | Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia. ( Bhasin, N; Desoky, SM; Price, N, 2022) |
| "Sickle cell anemia is the most common hemoglobinopathy worldwide; its musculoskeletal complications consist more often of medullary infarctions involving long bones." | 1.36 | [Orbital subperiosteal hematoma in child with sickle cell thalassemia. A case report]. ( Bellagha, I; Ben Hassine, L; Bouguila, H; Chebbi, A; Douira-Khomsi, W; Jarraya, M; Lahmar, L; Louati, H, 2010) |
| "In adults, pulmonary hypertension is significantly associated with mortality." | 1.35 | Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. ( Bazzy-Asaad, A; Carbonella, J; Friedman, A; Pashankar, FD, 2009) |
| "Hydroxyurea (HU) is a well-known chemotherapeutic agent that has been used largely for the treatment of various myeloproliferative conditions over the past 20 years." | 1.33 | Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. ( Darzi, H; Karimi, M; Yavarian, M, 2005) |
| "Obstructive sleep apnea can be caused by hypertrophy of tonsils and adenoids or neuromuscular diseases." | 1.31 | Upper airway obstruction-related sleep apnea in a child with thalassemia intermedia. ( Kapelushnik, J; Moser, A; Schulman, H; Shalev, H; Tamary, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.63) | 18.7374 |
| 1990's | 6 (13.95) | 18.2507 |
| 2000's | 17 (39.53) | 29.6817 |
| 2010's | 9 (20.93) | 24.3611 |
| 2020's | 6 (13.95) | 2.80 |
| Authors | Studies |
|---|---|
| Ricchi, P | 2 |
| Meloni, A | 1 |
| Rigano, P | 3 |
| Pistoia, L | 1 |
| Spasiano, A | 2 |
| Allò, M | 1 |
| Messina, G | 1 |
| Quarta, A | 1 |
| Rosso, R | 1 |
| Quota, A | 1 |
| Filosa, A | 2 |
| Maggio, A | 3 |
| Pepe, A | 1 |
| Lal, A | 1 |
| Bansal, D | 1 |
| Yasara, N | 1 |
| Wickramarathne, N | 1 |
| Mettananda, C | 1 |
| Manamperi, A | 1 |
| Premawardhena, A | 1 |
| Mettananda, S | 1 |
| Mohammadi, Z | 1 |
| Mohammadi, R | 1 |
| Haghpanah, S | 1 |
| Moghadam, M | 1 |
| Pazhoomand, R | 1 |
| Karimi, M | 2 |
| Rai, P | 1 |
| Joshi, VM | 1 |
| Goldberg, JF | 1 |
| Yates, AM | 1 |
| Okhomina, VI | 1 |
| Penkert, R | 1 |
| Ataga, KI | 2 |
| Kang, G | 1 |
| Hankins, JS | 1 |
| Bhasin, N | 1 |
| Price, N | 1 |
| Desoky, SM | 1 |
| Charan, S | 1 |
| Mishra, K | 1 |
| Jandial, A | 1 |
| Khadwal, A | 1 |
| Malhotra, P | 1 |
| Ansari, SH | 1 |
| Parveen, S | 1 |
| Siddiqui, S | 1 |
| Perveen, K | 1 |
| Ahmed, G | 1 |
| Kaleem, B | 1 |
| Ahmed, S | 1 |
| Zohaib, M | 1 |
| Farzana, T | 1 |
| Shamsi, T | 1 |
| Allali, S | 1 |
| Taylor, M | 1 |
| Albinni, S | 1 |
| Amiranoff, D | 1 |
| de Montalembert, M | 1 |
| Dehury, S | 1 |
| Purohit, P | 1 |
| Patel, S | 1 |
| Meher, S | 1 |
| Kullu, BK | 1 |
| Sahoo, LK | 1 |
| Patel, NK | 1 |
| Mohapatra, AK | 1 |
| Das, K | 1 |
| Patel, DK | 1 |
| Costantini, S | 1 |
| De Dominicis, G | 1 |
| Di Matola, T | 1 |
| Cinque, P | 1 |
| Ammirabile, M | 1 |
| Marsella, M | 1 |
| Couque, N | 1 |
| Girard, D | 1 |
| Ducrocq, R | 1 |
| Boizeau, P | 1 |
| Haouari, Z | 1 |
| Missud, F | 1 |
| Holvoet, L | 1 |
| Ithier, G | 1 |
| Belloy, M | 1 |
| Odièvre, MH | 1 |
| Benemou, M | 1 |
| Benhaim, P | 1 |
| Retali, B | 1 |
| Bensaid, P | 1 |
| Monier, B | 1 |
| Brousse, V | 1 |
| Amira, R | 1 |
| Orzechowski, C | 1 |
| Lesprit, E | 1 |
| Mangyanda, L | 1 |
| Garrec, N | 1 |
| Elion, J | 1 |
| Alberti, C | 1 |
| Baruchel, A | 1 |
| Benkerrou, M | 1 |
| Vasavda, N | 1 |
| Badiger, S | 1 |
| Rees, D | 1 |
| Height, S | 1 |
| Howard, J | 1 |
| Thein, SL | 2 |
| Pashankar, FD | 1 |
| Carbonella, J | 1 |
| Bazzy-Asaad, A | 1 |
| Friedman, A | 1 |
| Limaiem, F | 1 |
| Mekni, A | 1 |
| Nouira, K | 1 |
| Chelly, I | 1 |
| Bellil, K | 1 |
| Haouet, S | 1 |
| Kchir, N | 1 |
| Zitouna, M | 1 |
| Douira-Khomsi, W | 1 |
| Jarraya, M | 1 |
| Ben Hassine, L | 1 |
| Louati, H | 1 |
| Chebbi, A | 1 |
| Lahmar, L | 1 |
| Bouguila, H | 1 |
| Bellagha, I | 1 |
| Terpos, E | 1 |
| Voskaridou, E | 1 |
| Desai, PC | 1 |
| Deal, AM | 1 |
| Brittain, JE | 1 |
| Jones, S | 1 |
| Hinderliter, A | 1 |
| Datta, S | 1 |
| Fibach, E | 1 |
| Bianchi, N | 1 |
| Borgatti, M | 1 |
| Prus, E | 1 |
| Gambari, R | 1 |
| La Spina, M | 1 |
| Russo, G | 1 |
| Kattamis, A | 2 |
| Lagona, E | 1 |
| Orfanou, I | 1 |
| Psichou, F | 1 |
| Ladis, V | 1 |
| Kanavakis, E | 1 |
| Metaxotou-Mavrommati, A | 1 |
| Kattamis, C | 1 |
| Darzi, H | 1 |
| Yavarian, M | 1 |
| Gaziev, J | 1 |
| Sodani, P | 1 |
| Polchi, P | 1 |
| Andreani, M | 1 |
| Lucarelli, G | 1 |
| Fathallah, H | 1 |
| Sutton, M | 1 |
| Atweh, GF | 1 |
| Mancuso, A | 1 |
| Renda, D | 2 |
| Di Marzo, R | 1 |
| Borgna-Pignatti, C | 1 |
| Mellouli, F | 1 |
| Bejaoui, M | 1 |
| Adamson, JW | 1 |
| Rochette, J | 1 |
| Craig, JE | 1 |
| Loukopoulos, D | 1 |
| Lima, CS | 1 |
| Arruda, VR | 1 |
| Costa, FF | 1 |
| Saad, ST | 1 |
| Hattori, Y | 1 |
| Rodgers, GP | 1 |
| Renda, MC | 1 |
| Aquino, A | 1 |
| Mundee, Y | 1 |
| Bigelow, NC | 1 |
| Davis, BH | 1 |
| Porter, JB | 1 |
| Kapelushnik, J | 1 |
| Shalev, H | 1 |
| Schulman, H | 1 |
| Moser, A | 1 |
| Tamary, H | 1 |
| Stamatoyannopoulos, JA | 1 |
| Nienhuis, AW | 3 |
| Dover, GJ | 2 |
| Ley, TJ | 2 |
| Humphries, RK | 1 |
| Young, NS | 1 |
| Dover, G | 1 |
| Charache, S | 1 |
| Nora, R | 1 |
| Boyer, SH | 1 |
| Platt, OS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan[NCT03651102] | Phase 2/Phase 3 | 654 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| Obesity in Pediatric Sickle Cell Disease: A New Phenomenon[NCT04676113] | 100 participants (Actual) | Observational | 2021-03-01 | Completed | |||
| A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease[NCT04432623] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2020-10-05 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for hydroxyurea and Thalassemias
| Article | Year |
|---|---|
Thalassemia: Common Clinical Queries in Management.
Topics: beta-Thalassemia; Blood Transfusion; Chelation Therapy; Humans; Hydroxyurea; India; Splenectomy; Tha | 2020 |
Transfusing children with hemoglobinopathies.
Topics: Allografts; Anemia, Sickle Cell; Child; Emergencies; Erythrocyte Transfusion; Exchange Transfusion, | 2019 |
New drugs for childhood anemia.
Topics: Adult; Age Factors; Anemia; Anemia, Hemolytic, Autoimmune; Anemia, Sickle Cell; Antibodies, Monoclon | 2003 |
Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Combined Modality Therapy; Drug Approval; Drug Evaluation | 2005 |
Modern treatment of thalassaemia intermedia.
Topics: Blood Transfusion; Chelation Therapy; Fetal Hemoglobin; Humans; Hydroxyurea; Iron Chelating Agents; | 2007 |
Fetal hemoglobin levels in adults.
Topics: Adult; Azacitidine; Base Sequence; Butyrates; Butyric Acid; Fetal Hemoglobin; Gene Expression Regula | 1994 |
New therapies for the haemoglobinopathies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Butyrates; Butyric Acid; Drug Therapy, Combination; Erythr | 1997 |
[Diagnosis and therapy of hemoglobinopathies].
Topics: Antisickling Agents; Bone Marrow Transplantation; Globins; Hemoglobinopathies; Humans; Hydroxyurea; | 1999 |
Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Fetal Hemoglobin; Gene Expression Regulat | 1992 |
Pharmacologic manipulation of fetal hemoglobin. Update on clinical trials with hydroxyurea.
Topics: Anemia, Sickle Cell; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Thalassemia | 1990 |
Induction of hemoglobin F synthesis in patients with beta thalassemia.
Topics: Animals; Azacitidine; DNA; Erythroblasts; Female; Fetal Hemoglobin; Gene Expression Regulation; Glob | 1985 |
5 trials available for hydroxyurea and Thalassemias
| Article | Year |
|---|---|
Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial.
Topics: Adolescent; Adult; beta-Thalassemia; Double-Blind Method; Humans; Hydroxyurea; Quality of Life; Rand | 2020 |
Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Erythrocyte Indices; Erythrocyte Transfusion; Female; | 2004 |
Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia.
Topics: Adult; Antisickling Agents; Blood Cell Count; Bone Marrow Diseases; Female; Heterozygote; Hospitaliz | 2001 |
Pharmacologic manipulation of fetal hemoglobin. Update on clinical trials with hydroxyurea.
Topics: Anemia, Sickle Cell; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Thalassemia | 1990 |
Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Bone Marrow; Cells, Cultured; Clinical Trials as Topic; E | 1985 |
28 other studies available for hydroxyurea and Thalassemias
| Article | Year |
|---|---|
The use of hydroxyurea in the real life of MIOT network: an observational study.
Topics: Adult; beta-Thalassemia; Female; Hemoglobins; Humans; Hydroxyurea; Middle Aged; Thalassemia; Young A | 2022 |
Association of Exon 14 of the
Topics: Alleles; Antisickling Agents; Biomarkers; Cross-Sectional Studies; Erythrocyte Indices; Exons; Femal | 2020 |
Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Prospective Studies; Thalassemia; Tricuspid | 2021 |
Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Child, Preschool; Humans; Hydroxyurea; Male; Osteonecrosis; T | 2022 |
Melanonychia.
Topics: Adult; Humans; Hydroxyurea; Male; Melanosis; Nail Diseases; Nails; Splenomegaly; Thalassemia | 2018 |
Managing thalassemia in the developing world: an evidence-based approach for prevention, transfusion independency, and curative treatment with hematopoietic stem cell transplantation.
Topics: Blood Transfusion; Capacity Building; Developing Countries; Disease Management; Evidence-Based Medic | 2018 |
Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Fertility; Hemoglobin, Sickle; Humans; Hydroxyur | 2015 |
The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.
Topics: Antisickling Agents; Blood Transfusion; Bone Marrow; Drug Administration Schedule; Female; Fetal Hem | 2016 |
Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Female; Follow-U | 2016 |
The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Topics: Adolescent; Adult; alpha-Globins; Anemia, Sickle Cell; Antisickling Agents; Child; Drug Monitoring; | 2008 |
Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease.
Topics: Adolescent; Adult; Antisickling Agents; Child; Echocardiography, Doppler; Female; Follow-Up Studies; | 2009 |
Presacral extramedullary haematopoiesis.
Topics: Blood Transfusion; Enzyme Inhibitors; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Lumbosacra | 2009 |
[Orbital subperiosteal hematoma in child with sickle cell thalassemia. A case report].
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Diseases; Child; Eye; Functional Laterality; Hematoma | 2010 |
Treatment options for thalassemia patients with osteoporosis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Calcitonin; Clinical Trials as Topic; Defer | 2010 |
Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease.
Topics: Adolescent; Adult; Age Distribution; Aged; Anemia, Sickle Cell; Bilirubin; Blood Pressure; Body Mass | 2012 |
Treatment of thalassoemia--the current scenario.
Topics: Azacitidine; Bone Marrow Transplantation; Deferiprone; Fetal Hemoglobin; Genetic Therapy; Humans; Hy | 2002 |
Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells.
Topics: Actins; Cell Culture Techniques; Cell Differentiation; Cell Division; Erythroid Precursor Cells; Ery | 2003 |
Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Topics: Adolescent; Adult; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Female; Glycated | 2005 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical | 2005 |
Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up.
Topics: Adolescent; Adult; Follow-Up Studies; Humans; Hydroxyurea; Middle Aged; Nucleic Acid Synthesis Inhib | 2006 |
Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy.
Topics: Antisickling Agents; Child; Child, Preschool; Complementary Therapies; Female; Humans; Hydroxyurea; | 2007 |
[The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Topics: Anemia, Sickle Cell; Child; Heterozygote; Homozygote; Hospitalization; Humans; Hydroxyurea; Length o | 2008 |
Hemoglobin--from F to A, and back.
Topics: Anemia, Sickle Cell; Azacitidine; DNA; Fetal Hemoglobin; Humans; Hydroxyurea; Methylation; Thalassem | 1984 |
Minimal doses of hydroxyurea for sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Thalassemia | 1997 |
Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes.
Topics: Anemia, Sickle Cell; Anticoagulants; Erythrocyte Indices; Erythrocytes; Fetal Hemoglobin; Flow Cytom | 2001 |
Upper airway obstruction-related sleep apnea in a child with thalassemia intermedia.
Topics: Airway Obstruction; Blood Transfusion; Child, Preschool; Hematopoiesis, Extramedullary; Humans; Hydr | 2001 |
Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia.
Topics: Azacitidine; Fetal Hemoglobin; Globins; Humans; Hydroxyurea; Iron; Kinetics; RNA; Thalassemia; Time | 1985 |
Chemotherapy to increase fetal hemoglobin in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Azacitidine; Cytarabine; Fetal Hemoglobin; Humans; Hydroxyurea; Kinetics; Thala | 1985 |